-+ 0.00%
-+ 0.00%
-+ 0.00%

Longeveron elects Deborah Ascheim to board of directors

PUBT·07/23/2026 13:15:23
Listen to the news
Longeveron elects Deborah Ascheim to board of directors
  • Deborah D. Ascheim, M.D., elected to the board on July 23, 2026.
  • Ascheim is fractional chief medical officer at Rejuvenate Bio.
  • Previously chief medical officer at StrideBio, Capricor Therapeutics; founder-president of d2a Ltd., an independent biotech development consultancy.
  • Board addition comes as Longeveron advances laromestrocel, with hypoplastic left heart syndrome flagged as its most near-term catalyst.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230915PRIMZONEFULLFEED9766622) on July 23, 2026, and is solely responsible for the information contained therein.